BioCentury
ARTICLE | Clinical News

Avelumab: Additional Phase Ib data

May 23, 2016 7:00 AM UTC

Data from a cohort of 145 patients with previously untreated NSCLC in the open-label, dose-escalation, international Phase Ib JAVELIN Solid Tumor trial showed that 10 mg/kg IV avelumab every 2 weeks l...